Due to the unique structure of circular RNAs (circRNAs) and their widespread presence in body fluids, circRNAs are considered to have the potential as tumor biomarkers. At present, real-time fluorescent quantitative polymerase chain reaction (PCR) technology is thought as one of the main detection methods for molecular diagnosis in clinical practice. However, this technology has limitations with relatively higher false negatives. The digital PCR technology, the third generation PCR, optimizes and improves the detection sensitivity. More important, it does not require a standard curve to achieve absolute quantitative detection, which greatly improving the accuracy of detection, especially for the detection of low-expressed RNAs. In this study, to establish a new method for the quantitative detection of circRNAs in plasma, hsa_circ_0061276 was used as an example. Its specific primers were first designed, and then the economical droplet digital PCR (ddPCR) EvaGreen dye method was used to determine its absolute copy number in plasma samples from 12 patients with gastritis and 13 patients with gastric cancer. Besides, a negative control (without template) was set. The results showed that the total number of droplets in all samples exceeded 14 000. The absolute copy numbers in patients with gastritis are 2.90 Copies/μl, 2.20 Copies/μl, 3.20 Copies/μl, 1.40 Copies/μl, 3.00 Copies/μl, 1.02 Copies/μl, 0.81 Copies/μl, 0.41 Copies/μl, 1.40 Copies/μl, 0.69 Copies/μl, 0.41 Copies/μl, and 2.30 Copies/μl, respectively. The absolute copy numbers in patients with gastric cancer are 1.80 Copies/μl, 2.30 Copies/μl, 0.90 Copies/μl, 0.62 Copies/μl, 0.06 Copies/μl, 3.30 Copies/μl, 0.26 Copies/μl, 0.59 Copies/μl, 1.04 Copies/μl, 0.65 Copies/μl, 0.06 Copies/μl, 1.38 Copies/μl, and 0.18 Copies/μl, respectively. The bands of positive droplets and negative droplets are clearly distinguished, indicating that the specific copy number of hsa_circ_0061276 in plasma has been successfully detected. In conclusion, ddPCR may become a new technology for the detection of DNA/RNA-based biomarkers in biomedical researches and clinical applications with greater promotion value.